Rituxan safety study for boys with Duchenne muscular dystrophy
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This trial tests the safety of a drug called Rituxan in boys aged 6-10 with Duchenne muscular dystrophy (DMD) who can still walk independently. It aims to see if Rituxan is safe and tolerable for this group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a boy between 6 and 10 years old (including age 10).
- Have a genetic diagnosis of Duchenne muscular dystrophy (DMD).
- Be able to walk on your own and complete a 10-meter walk test.
- Be able to get up from lying on your back in less than 30 seconds.
- Be willing to have at least one muscle biopsy (a small sample taken from a muscle).
- Not have used oral steroid hormones for more than 6 months before the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new medicine called zeleciment rostudirsen can help ambulatory (walking) males with Duchenne muscular dystrophy (DMD). The medicine is given as an intravenous infusion (through a vein) every 4 weeks and works by helping the body produce a protective muscle protein.
This early-phase study tests a new gene therapy called BBM-D101 for boys with Duchenne muscular dystrophy (DMD). The goal is to see if it is safe and helps improve muscle function in young boys.
This long-term study is for people with Duchenne muscular dystrophy who have already completed an earlier trial of the study medicine. It aims to check the safety and effectiveness of the treatment over a longer period.
This study continues treatment with an investigational medicine called BMN 351 for people with Duchenne muscular dystrophy (a genetic muscle-weakening condition). It checks whether the medicine remains safe and effective when used over a longer period, building on results from an earlier trial.
This trial tests a new gene therapy called SPOT-03 to see if it can help the body make dystrophin, a protein that is missing in Duchenne muscular dystrophy (DMD). It is for boys ages 2 to under 8 who can still walk at least 10 meters.
This study tests a new gene therapy called BBM-D101 for boys with Duchenne muscular dystrophy. The goal is to see if it is safe and can help improve muscle function. It is for boys aged 4 to 8 who can still walk.
Hear when a new Duchenne Muscular Dystrophy (DMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.